At the time of writing, Monopar Therapeutics Inc [MNPR] stock is trading at $70.0, up 1.35%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MNPR shares have gain 11.11% over the last week, with a monthly amount drifted -2.06%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monopar Therapeutics Inc [NASDAQ: MNPR] stock has seen the most recent analyst activity on January 09, 2026, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $115. Previously, Raymond James downgraded its rating to Outperform on November 14, 2025. On November 10, 2025, Leerink Partners initiated with a Outperform rating and assigned a price target of $115 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $125 on October 13, 2025. BTIG Research initiated its recommendation with a Buy and recommended $87 as its price target on September 09, 2025. Raymond James started tracking with a Strong Buy rating for this stock on September 03, 2025, and assigned it a price target of $80. In a note dated September 03, 2025, Oppenheimer initiated an Outperform rating and provided a target price of $77 on this stock.
For the past year, the stock price of Monopar Therapeutics Inc fluctuated between $26.06 and $105.00. Currently, Wall Street analysts expect the stock to reach $108.38 within the next 12 months. Monopar Therapeutics Inc [NASDAQ: MNPR] shares were valued at $70.0 at the most recent close of the market. An investor can expect a potential return of 54.83% based on the average MNPR price forecast.
Analyzing the MNPR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.26 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Monopar Therapeutics Inc [NASDAQ:MNPR] has a current ratio of 56.10. In addition, the Quick Ratio stands at 56.10 and the Cash Ratio stands at 49.71.
Transactions by insiders
Recent insider trading involved Vu Quan Anh, Chief Financial Officer, that happened on Dec 26 ’25 when 1500.0 shares were purchased. Board Member, Arthur Klausner completed a deal on Dec 18 ’25 to buy 5121.0 shares. Meanwhile, Director KLAUSNER ARTHUR J sold 5121.0 shares on Dec 18 ’25.
